CIBC Private Wealth Group
ANIP icon

CIBC Private Wealth Group’s ANI Pharmaceuticals ANIP Stock Holding History

CIBC Private Wealth Group’s Portfolio ANIP Stock Details ANIP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		$316 Buy
+4
New +$346 ﹤0.01% 3131

Other funds holding ANIP

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
GACM
Global Alpha Capital Management Montreal, Quebec, Canada $1.67B AUM 35.09% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

CIBC Private Wealth Group's ANIP Position: Q4 2025 in Review

CIBC Private Wealth Group opened a new position in ANI Pharmaceuticals (ANIP) in Q4 2025: 4 shares worth $316. The stake represents ﹤0.01% of the portfolio and ranks #3131 among its holdings.

284 funds tracked by Wall St. Rank hold ANIP as of Q4 2025.

  • CIBC Private Wealth Group held 4 shares of ANI Pharmaceuticals worth $316 as of Q4 2025.
  • ANI Pharmaceuticals was a new CIBC Private Wealth Group position in Q4 2025.
  • ANI Pharmaceuticals made up ﹤0.01% of CIBC Private Wealth Group's portfolio in Q4 2025, its #3131 holding.
  • 284 funds tracked by Wall St. Rank held ANI Pharmaceuticals as of Q4 2025.

Based on CIBC Private Wealth Group's 13F filing for Q4 2025, filed 12 Feb 2026.